UBS lowered the target price for Wuxi Bio (02269) to HKD16.6 from HKD17.6 and maintained the "neutral" rating.
The research house said it fine-tuned its model and trimmed 2024/25 EPS estimates by 7.3%/6.3%.
【你點睇】的士業「放蛇」舉報Uber,政府應否將網約車合法化?你是否支持該類自行「放蛇」行為?► 立即投票